Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | REGN5837 |
| Trade Name | |
| Synonyms | REGN-5837|REGN 5837 |
| Drug Descriptions |
REGN5837 is a bispecific antibody that targets CD28 and CD22, resulting in crosslinking of tumor cells expressing CD22 to T cells expressing CD28, which potentially leads to increased antitumor immune response (PMID: 36350988). |
| DrugClasses | CD28 Antibody 12 |
| CAS Registry Number | NA |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Odronextamab + REGN5837 | Odronextamab REGN5837 | 0 | 1 |
| REGN5837 | REGN5837 | 0 | 0 |